News

Video

BDTX-1535 – A MasterKey EGFR Inhibitor Targeting Classical, Non-Classical, and the C797S Resistance Mutation to Address the Evolved Landscape of EGFR Mutant NSCLC

Author(s):

Christine M. Lovly, MD, PhD

Christine Lovly, MD, PhD, shares data on BDTX-1535, a “masterkey” EGFR inhibitor targeting classical, non-classical, and the C797S resistance mutation in patients with EGFR mutant non-small cell lung cancer (NSCLC), from a presentation at AACR 2024.

Related Videos
Xiuning Le, MD, PhD, of The University of Texas MD Anderson Cancer Center
Natasha B. Leighl, MD, BSc, MMSc, of the Princess Margaret Cancer Centre
John V. Heymach, MD, PhD, chair, Thoracic/Head and Neck Medical Oncology, and the David Bruton Endowed Chair in Cancer Research, The University of Texas MD Anderson Cancer Center
Yi-Long Wu, MD, PhD, of the Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University
Triparna Sen, PhD, of Icahn School of Medicine at Mount Sinai
Alexander I. Spira MD, PhD, FACP, FASCO, of Virginia Cancer Specialists
Sandip P. Patel, MD
Alissa J. Cooper, MD
Joshua K. Sabari, MD
Eric Kumar Singhi, MD
Related Content
John V. Heymach, MD, PhD
September 10th 2024

Perioperative Durvalumab Regimen Upholds EFS Benefit in Resectable NSCLC

Narjust Florez, MD
September 5th 2024

Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions

Jacob Sands, MD
September 10th 2024

Tarlatamab Sustains Responses, Shows Long-Term Tolerability in Heavily Pretreated SCLC

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Vlad Vitoc, MD, chairman, chief executive officer, MAIA Biotechnology
September 10th 2024

THIO Followed by Cemiplimab Leads to Potential OS Benefit in Pretreated Advanced NSCLC

Luis Raez, MD
September 10th 2024

Proteomics and Prognostics May Serve as Potential Biomarkers Beyond PD-L1 in Lung Cancer